Psilocybin Study for Smoking Cessation

A new study conducted by a team at Johns Hopkins University suggests that psilocybin, the active ingredient found in magic mushrooms, may be an effective treatment for smoking cessation. The trial compared the efficacy of a single dose of psilocybin against nicotine patches over a six-month period.

Remarkable Efficacy Uncovered

Participants who received psilocybin demonstrated more than six times greater odds of remaining abstinent from cigarettes compared to those relying on nicotine substitutes.

Out of 82 current smokers involved, 17 participants in the psilocybin group had stayed off cigarettes at the six-month mark, while only four in the nicotine group achieved this.

All participants in the study also underwent 13 weeks of cognitive behavioral therapy for smoking cessation. Matthew Johnson, the study's author and a professor of psychiatry at Johns Hopkins, expressed surprise at the significant effect observed.

The Therapeutic Mechanism

The study participants ingested a relatively high dose of pure psilocybin and were supported by facilitators in a comfortable setting. Psilocybin is believed to induce a shift in perspective and a new sense of agency, unlike current smoking cessation medications that often target nicotine receptors.

Addiction psychiatrist Dr. Brian Barnett noted that the intensive therapeutic support likely played a crucial role, harnessing the "neuroplastic and learning effects" post-drug exposure.

A New Path in Public Health

Smoking remains the leading cause of preventable death in the U.S., highlighting the urgent need for novel approaches. Megan Piper, director of the UW Center for Tobacco and Research Intervention, highlighted that it has been 20 years since a new medication for quitting smoking was introduced.

Existing medications combined with counseling typically result in a 20-30% long-term success rate per attempt.

The findings, published in JAMA Network Open, need replication in larger and more diverse studies.

While this trial did not include a placebo, a larger, ongoing trial funded by the National Institutes of Health, which includes a placebo arm, is currently underway to further investigate these promising results. Brain imaging results from the latest study are being analyzed to provide further insights into how the treatment works.